Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
2024年8月1日 - 9:00PM
- A sponsored exhibitor session will
feature Dr. Phillip Michaels from Harvard Medical School and
Brigham and Women’s Hospital presenting data from a multi-site
study evaluating the performance and benefits of optical genome
mapping (OGM) in comparison to classical methods for hematological
malignancies
- Two scientific poster
presentations from researchers at Vancouver General Hospital and
Dartmouth Hitchcock Medical Center will illustrate the application
of Bionano’s OGM workflow in blood cancer research
- Three scientific posters featuring
results from OGM applications in cancer will be on display at the
conference
SAN DIEGO, August 1, 2024 (GLOBE NEWSWIRE)
– Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation at the Cancer Genomics Consortium (CGC) 2024 Annual
Meeting with a broad range of content covering the utility of
optical genome mapping (OGM) for hematological malignancy cancer
research, including scientific poster presentations and an
exhibitor session featuring data from a multi-site study evaluating
OGM’s utility for evaluating hematological malignancies.
CGC’s annual meeting brings together industry, medical, and
academic professionals to discuss advances in clinical genomics for
oncology research. CGC conference sessions will be held August 4-7,
2024, online and in-person in St. Louis, Missouri.
As part of a sponsored session, Dr. Phillip Michaels from
Harvard Medical School and Brigham and Women’s Hospital will
discuss a multi-site, multi-operator study comparing OGM to
classical cytogenetic methods for the analysis, interpretation and
reporting of clinically relevant variants in hematological
malignancies. Dr. Michaels will present the initial study results
that assessed consistency across sites, turnaround time, cost
effectiveness, concordance with standard methods, and increased
yield. The presentation will take place Monday, August 5, from
3:45-4:00 PM CDT in the General Ballroom at the
conference.
Two scientific presentations highlighting OGM as a novel
technique in blood cancer research applications will be given by
researchers from Vancouver General Hospital and Dartmouth Hitchcock
Medical Center.
In addition, three posters featuring results from OGM
applications in hematological malignancies and solid tumor research
will be on display at the conference.
Scientific presentations from Bionano customers include:
Session |
Title |
Presenter |
Presented |
Speed Abstracts Session I |
Interplatform comparison of Stratys and Saphyr: Preliminary results
of OGM verification in hematologic cancers |
McGinnis E. |
August 4, 20242:15-3:00 PM CDT |
Speed Abstracts Session III |
High resolution cytogenomic analysis reveals characterizing
abnormalities in APL-like leukemia |
Sathyanarayana S. |
August 5, 202412:30-1:00 PM CDT |
Exhibitor Showcase |
Improving sensitivity and workflow efficiency in myeloid malignancy
research with optical genome mapping: A multi-institutional
study |
Michaels P. |
August 5, 20243:45-4:00 PM CDTGrand Ballroom |
The following scientific posters from Bionano will be on display
Tuesday, August 6, from 4:30-6:00 PM CDT in the exhibit hall:
Title |
Author |
A new and efficient analysis and reporting workflow for
hematological malignancies evaluated by optical genome mapping |
Clifford B. |
Genome wide, high-throughput, high-resolution structural variation
detection at low variant allele fraction for oncology samples |
Lynch P. |
Isotachophoresis (ITP) for high-throughput isolation of UHMW gDNA
suitable for optical genome mapping (OGM) |
Yadav M. |
“Bionano is pleased to participate in the CGC conference this
year, with a variety of presentations and posters covering the
utility of our solutions for cancer research applications. We are
excited to share initial data from our hematological malignancy
multi-site study with CGC conference attendees, which compares OGM
to classical cytogenetic methods for the detection and reporting of
structural variants relevant to cancer prognosis and treatment. We
will also highlight the latest advancements to our VIA™ software
and Bionano Solve pipeline, which can help improve researchers’
ability to visualize, interpret and report results in a streamlined
process that can offer greater utility for the identification of
critical cancer signatures from a genome-wide perspective,”
commented Erik Holmlin, PhD, president and chief executive officer
of Bionano.
More details on the conference can be found here:
https://bionano.com/cgc-2024/.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through optical genome
mapping (OGM) solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. The Company also offers an
industry-leading, platform-agnostic genome analysis software
solution, and nucleic acid extraction and purification solutions
using proprietary isotachophoresis (ITP) technology. Through
its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also offers OGM-based
diagnostic testing services.
For more information,
visit www.bionano.com or www.bionanolaboratories.com.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “can,” “will,” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) convey uncertainty of future events or outcomes
and are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the potential of our
OGM workflows to be useful in research applications for
hematological malignancies; the utility of our OGM workflows in the
evaluation of hematological malignancies; the utility of OGM for
research in the areas reported in the presentations given and the
posters made available at the CGC 2024 Annual Meeting; the utility
of OGM compared to classical cytogenetic methods for the analysis,
interpretation and reporting of clinically relevant variants in
hematological malignancies; the ability and utility of our VIA
software and Bionano Solve pipeline to help improve researchers’
ability to visualize, interpret and report results in a streamlined
process that can offer greater utility for the identification of
critical cancer signatures from a genome-wide perspective; and
other statements that are not of historical fact. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of geopolitical and macroeconomic
developments, such as recent and potential future bank failures,
supply chain disruptions, global pandemics, inflation and the
ongoing conflicts between Ukraine and Russian and Israel and Hamas,
on our business and the global economy; general market conditions;
changes in the competitive landscape and the introduction of
competitive technologies or improvements to existing technologies;
failure of our OGM workflows to be useful in research applications
for hematological malignancies; failure of our OGM workflows to be
useful in the evaluation of hematological malignancies; failure of
OGM to prove useful for research in the areas reported in the
presentations given and the posters made available at the CGC 2024
Annual Meeting; failure of OGM to be useful when compared to
classical cytogenetic methods for the analysis, interpretation and
reporting of clinically relevant variants in hematological
malignancies; failure of our VIA software and Bionano Solve
pipeline to help improve researchers’ ability to visualize,
interpret and report results in a streamlined process that can
offer greater utility for the identification of critical cancer
signatures from a genome-wide perspective; failure of our OGM
solutions to offer the anticipated benefits for and contributions
to the areas reported in the presentations given and posters made
available at the CGC 2024 Annual Meeting; future study results
contradicting the results reported in the presentations given and
posters made available at the CGC 2024 Annual Meeting; changes in
our strategic and commercial plans; our need and ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts, our ability to effectively manage our
uses of cash, and our ability to continue as a “going concern”; the
ability of medical and research institutions to obtain funding to
support adoption or continued use of our technologies; and the
risks and uncertainties associated with our business and financial
condition in general, including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2023 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 7 2024 まで 8 2024
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 8 2023 まで 8 2024